AC-262 (Accadrine) + ACP-105 (Androxepen) | SARMs Research UK

Selective Muscle Tissue Research Set

The BioPlex Selective Muscle Tissue Research Set combines AC-262 (Accadrine) 50×15mg and ACP-105 (Androxepen) 50×15mg, bringing together two non-steroidal selective androgen receptor modulators for comparative laboratory investigation of androgen-receptor signalling, tissue-selective responses and differences between distinct experimental SARM compounds. The set contains one pot of each compound and provides a structured format for studying two molecules that share the androgen receptor as an important molecular target while retaining separate chemical structures and evidence profiles.

AC-262, also identified in scientific literature as AC-262,536, is particularly associated with research into selective androgen-receptor modulation and partial agonist behaviour. Published investigation has examined its receptor-binding characteristics, transcriptional activity and responses across experimental tissue models. This makes AC-262 particularly relevant to questions concerning whether androgen-receptor signalling can produce different patterns of activity according to ligand structure and biological environment.

ACP-105 is another experimental non-steroidal selective androgen receptor modulator associated with tissue-selective androgen-receptor research. Its molecular structure differs from AC-262, and the available research surrounding the two compounds should therefore be evaluated independently rather than assuming that membership of the same pharmacological category makes their behaviour equivalent.

The Selective Muscle Tissue Research Set name reflects the wider scientific interest surrounding tissue-selective androgen-receptor signalling. It does not imply that either compound will produce a predetermined experimental outcome.

By bringing AC-262 and ACP-105 together, BioPlex provides a comparative research pairing centred on two distinct androgen-receptor ligands. Researchers can examine similarities in their broad receptor pathway while considering differences in molecular structure, receptor activity, evidence depth and experimentally observed tissue responses. Both compounds are supplied as individually identified 50×15mg capsule products intended strictly for laboratory, analytical and educational research.

How AC-262 and ACP-105 Work Together

AC-262 (Accadrine) and ACP-105 (Androxepen) are connected principally through their classification as experimental selective androgen receptor modulators. The androgen receptor is a ligand-activated nuclear receptor that can regulate transcription of androgen-responsive genes following interaction with an appropriate ligand. This shared molecular target provides the principal scientific rationale for placing the compounds together within a comparative research set.

The term selective is important. SARM research has investigated whether structurally different androgen-receptor ligands can generate different patterns of receptor activation and tissue response rather than reproducing identical activity across every androgen-responsive experimental system. Ligand structure, receptor conformation, co-regulator recruitment, receptor density and cellular environment can all contribute to the resulting response.

AC-262 is particularly interesting because published research has described partial agonist characteristics within androgen-receptor investigation. Partial agonism means that receptor binding alone does not necessarily translate into the same maximal receptor response observed with a full agonist under comparable experimental conditions. BioPlex's existing AC-262 research material accordingly focuses on receptor signalling, partial agonism and tissue-selective research.

ACP-105 provides a second structurally distinct androgen-receptor ligand. Pairing it with AC-262 therefore allows researchers to consider whether separate compounds within the SARM category display differing receptor-associated responses when examined using equivalent analytical conditions.

This does not establish that AC-262 and ACP-105 are synergistic or that combining them produces an enhanced biological effect. Their scientific value as a pairing lies instead in comparative investigation.

Controlled research can examine receptor activation, transcriptional markers and tissue-dependent responses while maintaining clear separation between findings attributable to each compound. Appropriate controls, verified compound identity, defined experimental conditions and predetermined endpoints remain essential when interpreting observations involving either molecule.

AC-262 (Accadrine) 50×15mg

AC-262, commonly known as Accadrine and identified scientifically as AC-262,536, is a synthetic non-steroidal selective androgen receptor modulator investigated primarily through receptor-binding, transcriptional and preclinical research. It occupies an interesting position within the SARM category because published investigation has characterised it in relation to partial agonist activity at the androgen receptor and tissue-dependent experimental responses.

The androgen receptor is AC-262's principal molecular research target. As a nuclear receptor, it can influence transcription following ligand binding and subsequent interaction with regulatory proteins and androgen-response elements. However, receptor binding does not by itself determine the complete biological response. Ligand structure, receptor conformation, co-regulator recruitment and the characteristics of the experimental tissue can all influence downstream observations.

Published AC-262 research has concentrated substantially on early pharmacological and preclinical models. This distinguishes its evidence profile from SARMs such as Ostarine, which have progressed through considerably broader research programmes. BioPlex's comparative research material describes AC-262 as structurally distinct and highlights its association with partial agonist behaviour and tissue-selective androgen-receptor investigation.

This makes AC-262 useful when investigating an important principle within SARM pharmacology: compounds interacting with the same receptor do not necessarily generate identical levels or patterns of receptor activation.

Within the Selective Muscle Tissue Research Set, AC-262 therefore provides one side of a structured comparison between two distinct non-steroidal androgen-receptor ligands. Researchers can consider its documented partial-agonist characteristics alongside the separate molecular and experimental profile of ACP-105.

BioPlex also maintains dedicated educational material covering AC-262, including androgen-receptor signalling, SARM selectivity, partial agonist activity, tissue-marker research and analytical testing.

ACP-105 (Androxepen) 50×15mg

ACP-105, presented by BioPlex under the Androxepen name, is an experimental non-steroidal selective androgen receptor modulator associated with research into androgen-receptor signalling and tissue-selective pharmacology. Like other genuine SARMs, its scientific classification centres on interaction with the androgen receptor rather than unrelated metabolic, growth-hormone or nuclear-receptor pathways.

The androgen receptor functions as a ligand-regulated transcription factor. Interaction with an appropriate ligand can change receptor conformation and influence subsequent interactions with cellular co-regulators and DNA response elements. These processes can affect androgen-responsive transcription, although the resulting experimental profile depends upon both the ligand and the biological system in which it is studied.

ACP-105 is a distinct molecule and should therefore not be treated as interchangeable with AC-262 simply because both compounds belong to the broad SARM category. Differences in chemical structure may correspond with differences in receptor interaction, pharmacological characteristics and tissue-dependent responses. Compound-specific investigation is required to establish those differences.

This is particularly relevant within comparative SARM research. The objective is not simply to determine whether two molecules can interact with the same receptor. Researchers may instead investigate differences in receptor activation, transcriptional signalling, tissue selectivity and other predefined experimental endpoints.

Within the BioPlex Selective Muscle Tissue Research Set, ACP-105 provides a useful counterpart to AC-262. AC-262 brings a research profile particularly associated with partial agonism and early-stage tissue-selectivity investigation, while ACP-105 provides a separate androgen-receptor ligand for comparative analysis.

The current BioPlex SARMs catalogue identifies ACP-105 Androxepen as a 50×15mg research capsule product and lists it alongside AC-262 and other androgen-receptor research compounds.

Explore Related Research Compounds

Continue exploring related selective androgen receptor modulators from the BioPlex SARMs capsule range.

View AC-262 Accadrine 50×15mg Research Capsules ⟶

Explore ACP-105 Androxepen 50×15mg Research Capsules ⟶

View RAD-140 Testolone 50×15mg Research Capsules ⟶

Explore BioPlex Research Information

Access BioPlex SARMs guidance, compound classification and the complete research product range.

Read the Complete SARMs UK Research Compound Guide ⟶

Explore the BioPlex SARMs Research Range ⟶

View All BioPlex Research Products ⟶

Explore Related Research Articles

Continue your research with BioPlex articles covering AC-262 Accadrine, androgen-receptor signalling, partial agonist activity and comparative SARM research.

Read the AC-262 Accadrine Research Overview ⟶

Read AC-262 vs Ostarine MK-2866: Androgen-Receptor Research Compared ⟶

Explore All BioPlex SARMs Research Articles ⟶

Disclaimer

For research purposes only. Not for human consumption.